CM
MBX

Caption Management’s MBX Biosciences MBX Stock Holding History

Caption Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,000
Closed -$485K – 2166
2025
Q3 		$350K Buy
+20,000
New +$267K ﹤0.01% 1378

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Caption Management's MBX Position: Q4 2025 in Review

Caption Management sold out of MBX Biosciences (MBX) in Q4 2025, closing a stake of 20,000 shares — an estimated $485K sold.

Caption Management first reported a position in MBX in Q3 2025 and held it in 1 quarter. The position peaked at $350K in Q3 2025. 138 funds tracked by Wall St. Rank hold MBX as of Q4 2025.

  • Caption Management reported no remaining MBX Biosciences position as of Q4 2025 after selling out during the quarter.
  • Caption Management sold 20,000 MBX Biosciences shares in Q4 2025, an estimated $485K.
  • Caption Management first reported a position in MBX Biosciences in Q3 2025 and held it in 1 quarter.
  • Caption Management's MBX Biosciences position peaked at $350K in Q3 2025.
  • 138 funds tracked by Wall St. Rank held MBX Biosciences as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.